Every 8-K that SiNtx Technologies, Inc. (SINT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SINT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SINT filings page.
SINTX Technologies, Inc. reports that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity for continued listing. Based on SINTX’s Form 10-Q for the quarter ended June 30, 2026, Nasdaq’s Listing Qualifications Staff noted stockholders’ equity of $4,830,000 (approximately $4.83 million) and confirmed that the prior deficiency matter is now closed.
The company states that it remains focused on commercializing its silicon nitride-based medical products, expanding its distribution network, and developing strategic partnerships to support future revenue growth, while working to maintain compliance with Nasdaq’s continued listing requirements.
SINTX Technologies provided a mid‑year 2026 update tied to its June 30, 2026 quarter. The company advanced commercialization of its FDA‑cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, launching a Limited Use Release and building an initial network of twelve independent orthopedic distributors focused on foot and ankle surgery. Management highlighted expanding industrial ceramics activity, including approximately $3.2 million in new industrial purchase orders, with related revenue expected to begin in the third quarter of 2026 subject to delivery and revenue‑recognition requirements.
The company issued a revenue outlook of about $900,000–$1.1 million for the third quarter of 2026 and $1.0–$1.3 million for the fourth quarter, stressing that these expectations are highly uncertain and depend on production, shipment timing, customer acceptance and other factors. SINTX completed construction of a 3D‑printing facility to support future SiNERGY™ patient‑specific silicon nitride/PEEK implants and received an additional 12‑month period to access roughly $745,000 remaining on a $1.97 million NIH grant for porous silicon nitride/PEEK spinal fusion implants.
During the second quarter, SINTX raised approximately $5.0 million in gross proceeds through a private placement and sales under its at‑the‑market equity program and noted remaining ATM capacity. Management emphasized capital‑allocation and cost‑optimization efforts but acknowledged limited liquidity, ongoing operating losses, dependence on additional financing and explicitly referenced substantial doubt regarding the company’s ability to continue as a going concern.
SINTX Technologies, Inc. announced that it has engaged Southern Metrics Consulting, led by medical technology executive and SINTX board member Chris Lyons, to establish and manage a new Strategic Opportunity Management Program focused on enhancing stockholder value.
The program is intended to create a disciplined, proactive framework for identifying, evaluating, prioritizing, and managing strategic opportunities that support SINTX’s long-term growth strategy. Working with executive management and the board, Southern Metrics will assess options including commercial partnerships, licensing, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. The company notes that the engagement does not indicate any specific transaction is pending and there is no assurance any opportunity will be identified, pursued, completed, or successful.
SINTX Technologies entered a letter agreement with MedTech Ceramics to clean up prior warrant-related share arrangements and modify its capital structure. The company will release 255,267 common shares from abeyance and convert the remaining 251,987 abeyance shares into a pre-funded warrant for the same number of shares, all for consideration already paid in a September 2025 transaction. An existing warrant to purchase 760,881 shares will be cancelled and replaced with a new warrant to buy 1,268,135 shares at $2.14 per share. SINTX plans to file a resale registration statement for the shares underlying the new warrant within 45 days and notes that these steps are intended to help its efforts to improve stockholders’ equity, while actual equity levels will continue to depend on its broader financial condition.
SINTX Technologies entered securities purchase agreements for a private placement of 1,882,845 units at $2.39 per unit, raising approximately $4.5 million in gross proceeds. Each unit includes one common share plus Class A and Class B warrants, each to buy one share at an exercise price of $2.14.
The warrants cover 200% of the shares issued, with Class A expiring in five years and Class B in two years and subject to revenue-based forced exercise if quarterly revenue reaches at least $2.0 million. Together with a recent $500,000 at-the-market sale, SINTX has raised about $5.0 million of equity capital, which it plans to use for working capital, commercialization, business development and other strategic opportunities.
SINTX Technologies reported that Nasdaq has notified it of noncompliance with a key listing rule. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity, but SINTX reported about $904,000 of stockholders’ equity as of March 31, 2026.
The company also does not meet alternative Nasdaq standards based on market value of listed securities or net income. SINTX has 45 days, until July 6, 2026, to submit a plan to regain compliance and could receive up to 180 days from the notice date if Nasdaq accepts the plan. The notice does not immediately affect the listing or trading of the common stock, and SINTX is exploring equity financing and other balance sheet initiatives, though completion is not assured.
SINTX Technologies reported a leadership change and new executive employment terms. Effective March 16, 2026, Eric Olson will stop serving as President but will remain Chairman of the Board and Chief Executive Officer. On the same date, Ryan Elmore will become President and report to the CEO.
Elmore brings over 20 years of leadership experience in medical device and life sciences businesses, including senior commercial and international roles at Invibio, a division of Victrex plc. His executive employment agreement includes a base salary of $375,000 per year, a target annual cash bonus of 35% of base salary (with his first-year bonus guaranteed), and a $100,000 sign-on bonus payable at the start of employment.
Upon starting, he will also receive restricted stock units with a grant date value of $300,000, with 20% vesting immediately and the rest vesting in equal installments over 24 months, subject to continued employment, plus eligibility for additional equity awards tied to international business milestones. If his employment is terminated by the company without cause or by him for good reason, he is entitled to accrued compensation, a cash severance equal to two times his base salary plus target bonus, and up to 24 months of continued health coverage or equivalent cash payments, with enhanced protections in certain change in control situations.
SINTX Technologies furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1, which also discusses the company’s use of a non-GAAP financial measure.
The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference except as expressly stated. The Item 2.02 information is also included under Item 7.01 by reference.
SINTX Technologies established an at-the-market stock offering program to sell common shares with an aggregate offering price of $6,413,876 through H.C. Wainwright as sales agent. The program uses the company’s effective Form S-3 shelf registration and a new prospectus supplement.
Wainwright will receive a 3.0% commission on the gross sales price of any shares sold, plus reimbursement of specified expenses. SINTX is not required to sell any stock, can suspend the program at any time, and will designate the maximum amount of stock to be sold in each placement.
SiNtx Technologies, Inc. disclosed an agreement allowing holders to exercise existing warrants and receive new common stock purchase warrants. The holders may exercise existing warrants to acquire shares at $3.32 per share, and the company will issue New Warrants to purchase up to 1,649,147 common shares at $4.79 per share. Holders also agreed to pay $0.125 per New Warrant as consideration. The company expects to receive aggregate gross proceeds of approximately $3.8 million from exercise of the existing warrants, before placement agent fees and other offering expenses. The filing includes forms for the inducement letter, New Warrant, placement agent warrants and related exhibits, and is signed by CEO Eric K. Olson.
On 22 Jul 2025, SINTX Technologies (SINT) filed a Form 8-K (Item 7.01) to furnish a press release announcing it has submitted a 510(k) application to the U.S. Food & Drug Administration for silicon-nitride foot & ankle medical devices. The disclosure is informational only and is not deemed “filed” for liability purposes. No financial statements, revenue guidance, or cost estimates accompany the submission. While the filing marks a key regulatory milestone that could enable U.S. commercialization, the company did not provide an expected review timeline, market size, or projected financial impact.
SINTX Technologies (NASDAQ:SINT) filed an 8-K announcing a definitive Asset Purchase Agreement signed 23 Jun 2025 with Sinaptic Surgical to acquire substantially all foot-and-ankle implant assets. Consideration is warrants for up to 325,000 SINT shares at $6.30, vesting on FDA 510(k) clearance and cumulative revenue milestones of $2.5-$15 million, and expiring after five years. Sinaptic will also purchase 216,450 shares at $3.465 in a private placement. Upon exceeding $15 million net revenue within four years, Sinaptic earns a 5 % royalty on related sales for two years. Closing is targeted for 1 Jul 2025, subject to customary conditions, and SINTX will file a resale registration within 90 days. The deal provides immediate capital, broadens SINTX’s product pipeline, and aligns future dilution with commercial success.